Merck and ICx cancer theranostic pact:
This article was originally published in Clinica
Merck & Co has teamed up with ICx Technologies and Fred Hutchinson Cancer Research Center of Seattle to develop theranostic blood tests for cancer. The tests will look for nucleic acids in the blood that can help determine if certain cancer therapies are appropriate for a patient. Arlington, Virginia-based ICx will incorporate its data-rich molecular diagnosis technology - previously developed for security applications - into the tests. The research will be conducted at the company's La Jolla, California-based Biosystems unit.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.